Inhibiting Cancer-Helping Enzyme May Lead to Innovative Melanoma Therapy

PHILADELPHIA – Fox Chase Cancer Center researchers have found that inhibiting an enzyme critical to cancer cell repair and proliferation may represent a new potential strategy for treating melanoma. Their paper, entitled, “Thymine DNA glycosylase as a novel target for melanoma,” appears in the journal Oncogene.

“Melanoma is classified as a ‘recalcitrant cancer’ by the National Cancer Institute because it can be difficult to treat in its advanced stages due to drug resistance,” said Alfonso Bellacosa, MD, PhD, a professor of cancer epigenetics at Fox Chase, and senior author of the study. “Until check-point inhibitor immunotherapy became available, we had seen little advancement in therapeutic approaches, and new targets are urgently needed.” Leading authors of the study are Pietro Mancuso PhD and Rossella Tricarico PhD….More>>

2019-01-27T20:29:46+00:00
SPECIALE CORONAVIRUS
ULTIME NOTIZIE

MODULO DI ISCRIZIONE
Compilando il modulo si dimostra di apprezzare il lavoro della redazione nel fornire le notizie sulla lotta alla pandemia a livello globale e, nel contempo, si avrà la possibilità di restare aggiornati  sulle iniziative Koncept
ISCRIVITI

A NESSUNO PIACE LO SPAM
Per questo le informazioni di Koncept non hanno cadenza regolare e non contengono  materiale pubblicitario di terze parti. Informativa completa all'indirizzo: www.koncept.it/privacy
close-link